Checkpoint Therapeutics is a clinical-stage oncology company focused on developing and commercializing cancer treatments. Its lead product is UNLOXCYT (cosibelimab-ipdl), a PD-L1 blocking antibody that received FDA approval in December 2024 for adults with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC), a form of skin cancer, who are not candidates for curative surgery or radiation. UNLOXCYT works by blocking PD-L1, a protein that suppresses the immune system's ability to attack tumors, re-activating T-cells to target cancer cells. As of the filing date, Checkpoint had not yet generated product revenue. The company entered into a merger agreement with Sun Pharmaceutical Industries in March 2025, which is intended to facilitate the U.S. commercial launch of UNLOXCYT and international regulatory submissions. Checkpoint does not manufacture its own drugs, relying on third-party contract manufacturers, and its key drug candidates were licensed from third parties — primarily Dana-Farber Cancer Institute, NeuPharma, and Jubilant Biosys — meaning commercial success would trigger milestone and royalty payments to licensors. Beyond UNLOXCYT, Checkpoint has several early-stage pipeline programs, including CK-302 (anti-GITR), olafertinib (an oral EGFR inhibitor targeting NSCLC), CK-103 (a BET inhibitor), and CK-303 (anti-CAIX), none of which are expected to contribute to revenue in the near term. Checkpoint is a majority-controlled subsidiary of Fortress Biotech.